Animal models of depression: Challenges from a drug development perspective

Behavioural Pharmacology

Volumn 14, Issue 5-6, 2003, Pages 385-390

  Rupniak, Nadia M J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Animal models; Behavior; Depression; Drug development; Functional imaging

Indexed keywords

AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; APREPITANT; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; GLUCOCORTICOID RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SUBSTANCE P ANTAGONIST; VASOPRESSIN RECEPTOR ANTAGONIST;

BEHAVIORAL SCIENCE; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE MODEL; DRUG COST; DRUG EFFICACY; GENOMICS; HUMAN; IMAGING; LEARNED HELPLESSNESS; NONHUMAN; OLFACTORY BULBECTOMY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PSYCHOPHARMACOLOGY; SWIMMING; TAIL FLICK TEST; VALIDATION PROCESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE IMAGING; PSYCHOPHARMACOLOGY;

EID: 0141645449     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Beckman H, Moise H-W (1982). The cholinolytic biperiden in depression: an acute placebo-controlled study. Arch Gen Psychiat Nerven 231:213-220.
2. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF (2001). Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 21:516-521.
3. 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 22:7730-7736.
4. Enserink M (1999). Can the placebo be the cure? Science 284:238-240.
5. Feighner JP, Ehrensing RH, Kastin AJ, Leonard BE, Sverdlov L, Nicolau G, et al. (2000). A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression. J Affect Disord 61:119-126.
6. Feighner JP, Ehrensing RH, Kastin A J, Patel A, Sverdlov L, Hlavka J, et al. (2001). Double-blind, placebo-controlled study of INN 00835 (nemifitide) in the treatment of outpatients with major depression. Int Clin Psychopharmacol 16:345-352.
7. 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21:8188-8197.
8. Fuchs E, Kramer M, Hermes B, Netter P, Hiemke C (1996). Psychosocial stress in tree shrews: clomipramine counteracts behavioral and endocrine changes. Pharmacol Biochem Behav 54:219-228.
9. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, et al. (2002a). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natt Acad Sci USA 99:6370-6375.
10. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, et al. (2002b). 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S) -2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor (1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345.
11. Harlow HF, Suomi SJ (1971). Production of depressive behaviors in young monkeys. J Aut Child Schiz 1:246-255.
12. Hilakivi LA, Durcan MJ, Lister RG (1989). Effects of ethanol on fight- or swim-stressed mice in Porsolt's swim test. Neuropsychopharmacology 2:293-298.
13. Hlavka JJ, Nicolau G, Noble JF, Abajian H (1997). INN-00835. Drugs of the Future 22:1314-1320.
14. Horovitz ZP (1965). Selective block of rat mouse killing by antidepressants. Life Sci 4:1909-1912.
15. Kaufmann MW, Cassem NH, Murray GB, Jenike M (1984). Use of psychostimulants in medically ill patients with neurological disease and major depression. Can J Psychiat 29:46-49.
16. Kline NS, Li CH, Lehmann HE, Lajtha A, Laski E, Cooper T (1977). Beta-endorphin induced changes in schizophrenic and depressed patients. Arch Gen Psychiat 34:1111-1113.
17. Korte SM, de Kloet ER, Buwalda B, Bouman SD, Bohus B (1996). Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in forced swim test. Eur J Pharmacol 301:19-25.
18. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640-1645.
19. Kudriavtseva NN, Bakshtanovskaia IV, Popova NK (1989). The development of pathological forms of behavior in submissive male C57BL/6J mice during agonistic zoosocial interactions. A possible model of depression? Zh Vyssh Nerv Deiat Im IP Pavlova 39:1134-1141.
20. Leonard BE (1984). The olfactory bulbectomized rat as a model of depression. Pol J Pharmacol Pharm 36:561-569.
21. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA (2002). The functional neuroanatomy of the placebo effect. Am J Psychiat 159:728-737.
22. 1) antagonist L-733,060 in rat leamed helplessness, a chronic animal model of depression. Soc Neurosci Abs 25:31-15.
23. Mitchell PJ, Fletcher A (1993). Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology 32:1001-1009.
24. Melewijk HE, Hartog K, van der Poel AM, Mos J, Olivier B (1996). Reduction of guinea-pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology 128:31-38.
25. Overstreet DH, Janowsky DS, Gillin JC, Shiromani PJ, Sutin EL (1986). Stress-induced immobility in rats with cholinergic supersensitivity. Biol Psychiat 21:657-664.
26. Papolos DF, Edwards E, Marmur R, Lachman HM, Henn FA (1993). Effects of the antiglucocorticoid RU 38486 on the induction of learned helpless behavior in Sprague-Dawley rats. Brain Res 615:304-309.
27. Papp M, Vassout A, Gentsch C (2000). The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 115:19-23.
28. Ploghaus A, Narain C, Beckmann CF, Clare S, Bantick S, Wise R, et al. (2001). Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci 21:9896-9903.
29. Porsolt RD, Bertin A, Jalfre M (1977). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336.
30. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF (2000). Validity of clinical trials of antidepressants. Am J Psychiat 157:327-337.
31. Roehr J, Woods A, Corbett R, Kongsamut S (1995). Changes in paroxetine binding in the cerebral cortex of polydipsic rats. Eur J Pharmacol 278:75-78.
32. 1) receptors attenuates neonatal vocalisation in guinea pigs and mice. Neuropharmacology 39:1413-1421.
33. 1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497-508.
34. Sanchez C, Arnt J, Hyttel J, Moltzen EK (1993). The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology 110:53-57.
35. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA (2001). Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiat 50:651-658.
36. Sherman AD, Sacquitne JL, Petty F (1982). Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 16:449-454.
37. Steinberg R, Alonso R, Griebel G, Bert L, Jung M, Oury-Denat F, et al. (2001). Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 299:449-458.
38. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370.
39. Thase ME (1999). Hew should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiat 60 (suppl 4):23-31.
40. Thomson R (1982). Side effects and placebo amplification. Br J Psychiat 140:64-68.
41. van der Hart MG, Czeh B, de Biurrun G, Michaelis T, Watanabe T, Natt O, et al. (2002). Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiat 7:933-941.
42. Willner P (1984). The validity of animal models of depression. Psychopharmacology 83:1-16.
43. Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:319-329.
44. Willner P, Mitchell PJ (2002). The validity of animal models of predisposition to depression. Behav Pharmacol 13:169-188.
45. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987). Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 93:358-364.
46. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, et al. (2002). Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage 16:999-1014.
47. Woods SW, Tesar GE, Murray GB, Cassem NH (1986). Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiat 47:12-15.
48. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiat Res 34:171-181.